Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants
Luis Flórez , Daniel Echeverri-De la Hoz , Alfonso Calderón , Hector Serrano-Coll , Caty Martinez , Camilo Guzmán , Bertha Gastelbondo , German Arrieta , Ariel Arteta , Tania Márquez , Ricardo Rivero , Salim Máttar
{"title":"Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants","authors":"Luis Flórez , Daniel Echeverri-De la Hoz , Alfonso Calderón , Hector Serrano-Coll , Caty Martinez , Camilo Guzmán , Bertha Gastelbondo , German Arrieta , Ariel Arteta , Tania Márquez , Ricardo Rivero , Salim Máttar","doi":"10.1016/j.tmaid.2025.102820","DOIUrl":null,"url":null,"abstract":"<div><div>New immunogens against emerging new virus variants are essential for controlling new variants.</div></div><div><h3>Methods</h3><div>A preclinical study in which a receptor-binding domain (RBD) trimer was designed in silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. A three-dimensional model of the RBD-trimer was made, and the synthesis of the trimer was based on the RBD domain of the S protein of Beta and Omicron. For the experimental trials, 63 BALB/c mice were immunized and divided into three groups: control (n = 15), adjuvant (n = 15), and RBD-trimer (n = 33).</div></div><div><h3>Results</h3><div>81 % (13/16), 90 % (9/10), and 85 % (6/7) of BALB/c mice that received one dose, two doses, and three doses, respectively, seroconverted. Significant statistical differences (p < 0.001) were found between the experimental group vaccinated with the RBD-trimer, the group with adjuvant, and the control group. The booster did not show significant differences (p > 0.05. No inflammatory or cellular changes were observed, highlighting the safety of the RBD vaccine candidate. Kinetics and seroconversion of 75 % were obtained in the mice with two doses of tri-RBD. (P < 0.0001).</div></div><div><h3>Conclusions</h3><div>Applying two doses of the RBD vaccine candidate in BALB/c mice was safe and immunogenic against SARS-CoV-2. This study provides support for the country's biotechnological sovereignty and its potential contribution to public health in Colombia.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102820"},"PeriodicalIF":6.3000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893925000262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
New immunogens against emerging new virus variants are essential for controlling new variants.
Methods
A preclinical study in which a receptor-binding domain (RBD) trimer was designed in silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. A three-dimensional model of the RBD-trimer was made, and the synthesis of the trimer was based on the RBD domain of the S protein of Beta and Omicron. For the experimental trials, 63 BALB/c mice were immunized and divided into three groups: control (n = 15), adjuvant (n = 15), and RBD-trimer (n = 33).
Results
81 % (13/16), 90 % (9/10), and 85 % (6/7) of BALB/c mice that received one dose, two doses, and three doses, respectively, seroconverted. Significant statistical differences (p < 0.001) were found between the experimental group vaccinated with the RBD-trimer, the group with adjuvant, and the control group. The booster did not show significant differences (p > 0.05. No inflammatory or cellular changes were observed, highlighting the safety of the RBD vaccine candidate. Kinetics and seroconversion of 75 % were obtained in the mice with two doses of tri-RBD. (P < 0.0001).
Conclusions
Applying two doses of the RBD vaccine candidate in BALB/c mice was safe and immunogenic against SARS-CoV-2. This study provides support for the country's biotechnological sovereignty and its potential contribution to public health in Colombia.
期刊介绍：
Travel Medicine and Infectious Disease
Publication Scope:
Publishes original papers, reviews, and consensus papers
Primary theme: infectious disease in the context of travel medicine
Focus Areas:
Epidemiology and surveillance of travel-related illness
Prevention and treatment of travel-associated infections
Malaria prevention and treatment
Travellers' diarrhoea
Infections associated with mass gatherings
Migration-related infections
Vaccines and vaccine-preventable disease
Global policy/regulations for disease prevention and control
Practical clinical issues for travel and tropical medicine practitioners
Coverage:
Addresses areas of controversy and debate in travel medicine
Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease
Publication Features:
Offers a fast peer-review process
Provides early online publication of accepted manuscripts
Aims to publish cutting-edge papers
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
